| 979 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Special Situations |
17/06/2022 |
|
| 1872 |
Management of DR-TB ADR: Peripheral Neuropathy |
17/06/2022 |
|
| 1871 |
Management of DR-TB ADR: Hepatitis |
17/06/2022 |
|
| 1870 |
Management of DR-TB ADR: Rash, Allergy and Anaphylaxis Reaction |
17/06/2022 |
|
| 983 |
Eligibility Criteria for Longer Oral M/XDR-TB Regimen |
17/06/2022 |
|
| 1869 |
Management of DR-TB ADR: QT Prolongation |
17/06/2022 |
|
| 984 |
Treatment Extension in Isoniazid [H] Mono/Poly DR-TB Regimen |
17/06/2022 |
|
| 1866 |
Treatment Extension in Longer Oral M/XDR-TB Regimen |
17/06/2022 |
|
| 1865 |
Use of M/XDR-TB Regimen in Patients with Psychiatric Illness |
17/06/2022 |
|
| 1864 |
Use of M/XDR-TB Regimen in Patients with Seizure Disorders |
17/06/2022 |
|
| 1863 |
Role of Surgery in DR-TB Treatment |
17/06/2022 |
|
| 987 |
Management of DR-TB ADR: Gastrointestinal Symptoms [Gastritis and abdominal pain] |
17/06/2022 |
|
| 1861 |
Principles for Management of MDR/RR-TB in Children |
17/06/2022 |
|
| 988 |
Management of DR-TB ADR: Diarrhoea and/or Flatulence |
17/06/2022 |
|
| 1860 |
Follow-up Evaluation of Patients on Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen |
17/06/2022 |
|
| 1857 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration |
17/06/2022 |
|
| 1856 |
Inclusion and Exclusion Criteria for the Use of Bedaquiline |
17/06/2022 |
|
| 1855 |
NTEP Services for Private Notified DR-TB Patients |
17/06/2022 |
|
| 999 |
Management of DR-TB Patients: Lost to Follow-up |
17/06/2022 |
|
| 1014 |
Guidelines for Issuing Bedaquiline and Delamanid to the Patient |
20/06/2022 |
|
| 1015 |
Role of the State Drug Store [SDS] in the Constitution of Patient-wise Boxes |
20/06/2022 |
|
| 1019 |
Drugs Used in the Management of Adverse Events |
20/06/2022 |
|
| 1020 |
Rationale for Grouping of Anti-TB Drugs |
20/06/2022 |
|
| 1022 |
Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment |
20/06/2022 |
|
| 1021 |
Drugs Not Included in Groups A - C and Rationale for Non-inclusion |
20/06/2022 |
|
| 1024 |
Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment |
20/06/2022 |
|
| 1034 |
Key Messages for TB Counselling |
20/06/2022 |
|
| 1037 |
Pre-treatment Evaluation [PTE] of DR-TB Patients |
20/06/2022 |
|
| 1039 |
Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up |
20/06/2022 |
|
| 1041 |
Immune Reconstitution Inflammatory Syndrome [IRIS] |
20/06/2022 |
|
